RxDoctor Payments Data

Brian Whisenant, MD

Cardiovascular Disease · Murray, UTNPI 1750359253

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $255,040 of the $416,031 with a category attached, or 61.3%. 11 manufacturers reported payments, led by Edwards Lifesciences at 36.5% of the total. Among cardiovascular disease clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$416,031in general payments, 2019–2025

Across 582 payments — averaging $714.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$152K
  • Abbott$124K
  • Boston Scientific$112K
  • Merit Medical Systems Inc$12K
  • W. L. Gore & Associates, Inc.$8K
  • Biosense Webster, Inc.$6K
  • plus $2K from 5 others
$2,958,936in research payments, 2019–2025

Across 571 payments — averaging $5182.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$1.9M
  • Abbott$959K
  • Medtronic$43K
  • Boston Scientific$10K
  • W. L. Gore & Associates, Inc.$2K

What the payments were for

  • Consulting fees$255,04061%
  • Speaking & faculty fees$82,84120%
  • Travel & lodging$63,32215%
  • Food & beverage$14,8284%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$416,031 in reported general payments places this provider in the 95th percentile of 131 cardiovascular disease providers in Utah.

See all cardiovascular disease providers in Utah

Medicare billing

Part B allowed, 2024
$150,448
Medicare patients
256
Services billed
587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol65$57,212
JardianceEmpagliflozin17$18,583
Metoprolol Succinate27$542
Spironolactone32$445
Losartan Potassium28$346
ClopidogrelClopidogrel Bisulfate13$144
Atorvastatin Calcium25$116
Lisinopril12$106

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Murray

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →